SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Geneva: WHO, 2012.
  • 2
    Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 20952128.
  • 3
    Van Damme P, Ward J, Shouval D, Wioersma S, Zanetti A. Hepatitis B vaccines. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines, 6th edn, Philadelphia, PA, USA: Elsevier, 2012: 205234.
  • 4
    Van De Laar JW, Lopalco PL. Special issue: World Hepatitis Day – a timely reminder of the challenges ahead. Eurosurveillance 2008; 13(4–6): 181212.
  • 5
    World Health Organization Regional Office for the Eastern Mediterranean. The growing threats of hepatitis B and C in the Eastern Mediterranean Region: a call for action. Cairo: WHO, 2009 [EM/RC 56/3]. Available at: http://applications.emro.who.int/docs/EM_RC56_3_en.pdf (accessed 29 March 2013).
  • 6
    European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C in the EU Neighbourhood: Prevalence, Burden of Disease and Screening Policies. Stockholm: ECDC, 2010.
  • 7
    Chu JJ, Wormann T, Popp J et al. Changing epidemiology of Hepatitis B and migration–a comparison of six Northern and North-Western European countries. Eur J Public Health 2012; epub ahead of print, doi:10.1093/eurpub/cks067.
  • 8
    Meffre C, Le Strat Y, Delarocque-Astagneau E et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010; 82: 546555.
  • 9
    Machado MC, Santana P, Carreiro H, Nogueira H, Barroso R, Dias A et al. Cuidados de saúde materna e infantil a uma população de imigrantes. Rev Migrações 2007; 1: 103127 [Article in Portuguese].
  • 10
    Papaevangelou V, Hadjichristodoulou C, Cassimos D, Theodoridou M. Adherence to the screening program for HBV infection in pregnant women delivering in Greece. BMC Infect Dis 2006; 6: 84.
  • 11
    Elefsiniotis IS, Glynou I, Zorou I et al. Surveillance for hepatitis B infection in pregnant women in Greece shows high rates of chronic infection among immigrants and low vaccination-induced protection rates: preliminary results of a single-centre study. Eurosurveillance 2009; 14(9): 57.
  • 12
    Cavlek TV, Margan IG, Lepej SZ, Kolaric B, Vince A. Seroprevalence, risk factors, and hepatitis C virus genotypes in groups with high-risk sexual behavior in Croatia. J Med Virol 2009; 81: 13481353.
  • 13
    Kolarić B, Stajduhar D, Gajnik D, Rukavina T, Wiessing L. Seroprevalence of blood-borne infections and population size estimates in a population of injecting drug users in Croatia. Cent Eur J Public Health 2010; 18: 104109.
  • 14
    Bozicevic I, Lepej SZ, Rode OD et al. Prevalence of HIV and sexually transmitted infections and patterns of recent HIV testing among men who have sex with men in Zagreb, Croatia. Sex Transm Infect 2012; 88: 539544.
  • 15
    Elzouki A-N, Esmeo M-N, Samod M et al. Prevalence of Hepatitis B, C and HIV infection in Libya: a population- based nationwide seroepidemiological study. Liver International 2006; 26 (Suppl. 1): A20.
  • 16
    Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19: 560567.
  • 17
    Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887891.
  • 18
    Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378(9785): 7385.
  • 19
    Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection – not a vanishing disease in Europe. Hepatology 2007; 45: 13311332.
  • 20
    Cross TJS, Rizzi P, Horner M et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80: 277282.
  • 21
    Saudy N, Sugauchi F, Tanaka Y et al. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol 2003; 70: 529536.
  • 22
    Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009; 41: 689699.
  • 23
    Garcia-Fulgueiras A, García-Pina R, Morant C, de Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. J Viral Hepat 2011; 18: e453e460.
  • 24
    Croatian National Cancer Registry. Cancer incidence in Croatia 2010, Bulletin No.35. Available at: http://www.hzjz.hr/cancer/annual_rep.htm (accessed 29 March 2013).
  • 25
    Waked IA, Saleh SM, Moustafa MS, Raouf AA, Thomas DL, Strickland GT. High prevalence of hepatitis C in Egyptian patients with chronic liver disease. Gut 1995; 37: 105107.
  • 26
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Statistical Bulletin 2010: drug-related infectious diseases. Available at: http://www.emcdda.europa.eu/html.cfm/index103785EN.html?type=stats&stat_prefix=INF-6&stat_type=w88&order=stat_reference (accessed 29 March 2013).
  • 27
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2012 Annual Report on the State of the Drugs Problem in Europe. Lisbon: EMCDDA, 2012.
  • 28
    Weissing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicenta J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005–2010. Eurosurveillance 2011; 16(48): 913. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20031 (accessed 29 March 2013).
  • 29
    European Centre for Disease Prevention and Control (ECDC), European Centre for Monitoring of Drugs and Drug Addiction. Prevention and Control of Infectious Diseases among People Who Inject Drugs. Stockholm: ECDC, 2011. Available at: http://www.ecdc.europa.eu/en/publications/Publications/111012_Guidance_ECDC-EMCDDA.pdf (accessed 29 March 2013).
  • 30
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Figure HSR-3. Syringes distributed through specialised programmes per estimated IDU in 2009 or most recent year. Available at: http://www.emcdda.europa.eu/stats11/hsrfig 3 (accessed 29 March 2013).
  • 31
    Mathers BM, Degenhardt L, Ali H et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 10141028.
  • 32
    Ahmetagic S, Muminhodzic K, Cickusic E, Stojic V, Petrovic J, Tihic N. Hepatitis C infection in risk groups. Bosn J Basic Med Sci 2006; 6: 1317.
  • 33
    Abdel-Wahab MF, Zakaria S, Kamel M et al. High prevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994; 51: 563567.
  • 34
    National Network of Epidemiological Surveillance. Reported Outbreaks of Hepatitis C, Spain 2006–2010. Madrid, Spain: Centro Nacional de Epidemiologia, 2011.
  • 35
    Martínez-Bauer E, Forns X, Armelles M et al. Hospital admission is a relevant source of hepatitis C acquisition in Spain. J Hepatol 2008; 48: 2027.
  • 36
    Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45: 607616.
  • 37
    Mansour AK, Aly RM, Abdelrazek SY et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther 2012; 5: 5459.
  • 38
    World Health Organization. The Global Patient Safety Challenge 2005–2006: Clean Care is Safer Care. Geneva: World Health Organization, 2005.
  • 39
    Telaku S, Fejza H. Prevalence of HBV and HCV among blood donors in Kosovo. Virol J 2009; 6: 21.
  • 40
    Hafner V. Blood Services in South-Eastern Europe: Current Status and Challenges. Copenhagen: World Health Organization Regional Office for Europe, 2007.
  • 41
    Hutin YJF, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003; 327: 1075.
  • 42
    Ben-Alaya-Bouafif N, Bahri O, Chlif S et al. Heterogeneity of hepatitis B transmission in Tunisia: risk factors for infection and chronic carriage before the introduction of a universal vaccine program. Vaccine 2010; 28: 33013307.
  • 43
    Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 716.
  • 44
    Toukan AU, Sharaiha ZK, Abu-El-Rub OA et al. The epidemiology of hepatitis B virus among family members in the Middle East. Am J Epidemiol 1990; 132: 220232.
  • 45
    Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779788.
  • 46
    Baklan Z, Gorisek JR, Poljak M, Pisec A. Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Marabor. Wien Klin Wochenschr 2004; 116(Suppl. 2): 57.
  • 47
    Burek V, Horvat J, Butorac K, Mikulic R. Viral hepatitis B, C and HIV infection in Croatian prisons. Epidemiol Infect 2010; 138: 16101620.
  • 48
    Babudieri S, Longo B, Sarmati L et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol 2005; 76: 311317.
  • 49
    Quinti I, Renganathan E, El Ghazzawi E et al. Seroprevalence of HIV and HCV infections in Alexandria, Egypt. Zentralbl Bakteriol 1995; 283: 239244.
  • 50
    van der Helm JJ, Prins M, del Amo J et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25: 10831091.
  • 51
    European Centre for Disease Prevention and Control (ECDC). Surveillance and Prevention of Hepatitis B and C in Europe. Stockholm: ECDC, 2010.
  • 52
    Zacharakis G, Kotsiou S, Papoutselis M et al. Changes in the epidemiology of hepatitis B virus infection following the implementation of immunisation programmes in northeastern Greece. Eurosurveillance 2009; 14(32): 1418.
  • 53
    Oviedo M, Munoz MP, Carmona G et al. The impact of immigration and vaccination in reducing the incidence of hepatitis B in Catalonia (Spain). BMC Public Health 2012; 12: 614.
  • 54
    National Centre for Disease Control and Prevention, Libya. Available at: www.nidcc.org.ly (accessed 29 March 2013).
  • 55
    Elzouki A-N. Hepatitis B infection in Libya: the magnitude of the problem. Libyan J Infect Dis 2008; 2: 2025.
  • 56
    Veldhuijzen IK, Toy M, Hahné SJ et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138: 522530.
  • 57
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705714.
  • 58
    Rein DB, Smith BD, Wittenborn JS et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263270.
  • 59
    Rossi C, Shrier I, Marshall L et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS ONE 2012; 7: e44611.
  • 60
    Yuen MF, Wong DK, Fung J et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 11921199.
  • 61
    Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168174.
  • 62
    Hatzakis A, Wait S, Bruix J et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepatitis 2011; 18(Suppl. 1): 116.
  • 63
    European Association for Study of the Liver (EASL). Clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167185.
  • 64
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507539.
  • 65
    Heathcote EJ, Marcellin P, Buti M et al. Three-year efficacy of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132143.
  • 66
    Marcellin P, Buti M, Gane EJ et al. Six years of treatment with tenofovir DF for chronic hepatitis B infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. In: Hepatitis B update: highlights from AASLD 2012. Available at: http://www.chronicliverdisease.org/disease_focus/ppts/ch/HBV_Highlights_from_AASLD2012.pdf (accessed 29 March 2013).
  • 67
    Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886.
  • 68
    Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during tenofovir disoproxil fumarate treatment for chronic hepatitis B. Lancet 2012; 381(9865): 468475.
  • 69
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730739.
  • 70
    Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA, for the Studies of the Ocular Complications of AIDS Research Group.. Mortality in hepatitis C-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55: 137144.
  • 71
    European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245264.
  • 72
    Buti M, Casado MA, Fosbrook L et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000; 33: 651658.
  • 73
    Di Marco V, Almasio PL, Ferraro D et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484491.
  • 74
    Bruno S, Stroffolini T, Colombo M et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579587.
  • 75
    Soriano V et al. Care of patients coinfected with HIV and hepatitis C virus: updated recommendations from the HCV-HIV international panel. AIDS 2007; 21: 10731089.
  • 76
    Manolakopoulos S, Deutsch MJ, Anagnostou O et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010; 30: 14541460.
  • 77
    Bruggmann P, Falcato L, Dober S et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15: 747752.
  • 78
    Pol S, Roberts SK, Andreone P et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with hcv genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology 2011; 54(Suppl. 1): 374A375A [Abstract no. 31].
  • 79
    Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012; 18: 60606069.
  • 80
    Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216224.
  • 81
    Poordad F, Lawitz E, Kowdley KV et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 4553.
  • 82
    Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 3444.
  • 83
    El-Zanaty F, Way A. Egypt Demographic and Health Survey, 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009. Available at: http://www.measuredhs.com (accessed 29 March 2013).
  • 84
    Mohamed MK, Abdel-Hamid M, Mikhail NN et al. Intrafamilial transmission of hepatitis C in Egypt. Hepatology 2005; 42: 683687.
  • 85
    Miller FD, Abu-Raddad LJ. Evidence of intense ongoing transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA 2010; 107: 1475714762.
  • 86
    Paez Jimenez A, Sharaf Eldin N, Rimlinger F et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010; 59: 15541560.
  • 87
    Khalifa AS, Mitchell BS, Watts DM et al. Prevalence of hepatitis C viral antibody in transfused and nontransfused Egyptian children. Am J Trop Med Hyg 1993; 49: 316321.
  • 88
    Abdel-Wahab MF, Zakaria S, Kamel M et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994; 51: 563567.
  • 89
    Abdel-Hamid M, El-Daly M, Molnegren V et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007; 88(pt 5): 15261531.
  • 90
    El Sayed N, Kandeel A, Genedy M et al. Progress toward prevention and control of hepatitis C virus infection – Egypt, 2001–2012. MMWR Morb Mortal Wkly Rep 2012; 61: 545549.
  • 91
    Obach D, Yazdanpanah Y, Esmat G et al. Impact of different treatment scale-up and eligibility scenarios on HCV mortality in Egypt in the next five years. Hepatology 2012; 56(S1): 1012A (AASLD 2012).